AAAAAA

   
Results: 1-13 |
Results: 13
Pathogenesis of diabetic nephropathy
Authors: Raptis, AE Viberti, G
Citation: Ae. Raptis et G. Viberti, Pathogenesis of diabetic nephropathy, EXP CL E D, 109, 2001, pp. S424-S437
Diabetic nephropathy: Prevention and treatment
Authors: Parving, HH Harrington, JT Lewis, J Boner, G Lewis, EJ Viberti, G Gilbert, R Raz, I Cooper, M Rossing, K
Citation: Hh. Parving et al., Diabetic nephropathy: Prevention and treatment, KIDNEY INT, 60(5), 2001, pp. 2041-2055
Diabetes mellitus: A major challenge in transplantation
Authors: Viberti, G
Citation: G. Viberti, Diabetes mellitus: A major challenge in transplantation, TRANSPLAN P, 33(5A), 2001, pp. 3S-7S
Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease
Authors: Thomas, S Vanuystel, J Gruden, G Rodriguez, V Burt, D Gnudi, L Hartley, B Viberti, G
Citation: S. Thomas et al., Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease, J AM S NEPH, 11(7), 2000, pp. 1236-1243
Cigarette smoking and diabetic nephropathy
Authors: Krimholtz, M Thomas, S Viberti, G
Citation: M. Krimholtz et al., Cigarette smoking and diabetic nephropathy, CONTR NEPHR, 130, 2000, pp. 85-93
Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension results of a randomized controlled trial - Results of a randomized controlled trial
Authors: O'Hare, JP Bilous, R Mitchell, T O'Callaghan, CJ Viberti, GC Willoughby, R Riley, J Robinson, AM Reckless, JP Havard, F Sampson, M Lloyd, A Williams, T Vora, J Chattington, P Hampson, K Ibrahim, H Borthwick, L Willoughby, R Viberti, G Russell, C Barnes, D Macklin, A Murphy, E Stephens, E Vincent, J Tindall, H Simpson, H Knowles, E Cunningham, B Simpson, E Bilous, R Bilous, M Mitchell, T O'Halloran, D Nugent, S Hadden, D Fetherstone, M McCarton, D McGurk, C Johnston, C Burton, J Harris, C Hempstead, H Baksi, A Bartlett, J Heaton, C Brown, K Arora, A Burke, J Najim, V Cassar, J Coppini, D Chazan, B Kennedy, R Smith, J Flynn, M Lewis, A Jeffcoate, W Peck, G Pound, N Large, D Clarke, M Llewellyn, H Ang, H Davidson, G McKenna, T Byrne, P Fiad, T Hayes, F McGra, J Peters, J Davies, M Press, M Price, D Jones, L Wareham, K Scarpello, J Hodgson, E Scott, R Chaudry, A Lord, G Parsons, D Smyth, C Tymms, D Fairhurst, M White, M Hepburn, D Beer, J Nasir, J Smith, C Lenox-Smith, A Braithwaite, I Riley, J Michael, A Seymour, I Laffealy, S Johnson, W Patel, S Halls, H Davall, H Schyns, C
Citation: Jp. O'Hare et al., Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension results of a randomized controlled trial - Results of a randomized controlled trial, DIABET CARE, 23(12), 2000, pp. 1823-1829
Mechanical stretch-induced fibronectin and transforming growth factor-beta1 production in human mesangial cells is p38 mitogen-activated protein kinase-dependent
Authors: Gruden, G Zonca, S Hayward, A Thomas, S Maestrini, S Gnudi, L Viberti, G
Citation: G. Gruden et al., Mechanical stretch-induced fibronectin and transforming growth factor-beta1 production in human mesangial cells is p38 mitogen-activated protein kinase-dependent, DIABETES, 49(4), 2000, pp. 655-661
Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells
Authors: Gruden, G Thomas, S Burt, D Zhou, WD Chusney, G Gnudi, L Viberti, G
Citation: G. Gruden et al., Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells, J AM S NEPH, 10(4), 1999, pp. 730-737
Neovascularization at the vascular pole region in diabetic glomerulopathy
Authors: Osterby, R Asplund, J Bangstad, HJ Nyberg, G Rudberg, S Viberti, G Walker, JD
Citation: R. Osterby et al., Neovascularization at the vascular pole region in diabetic glomerulopathy, NEPH DIAL T, 14(2), 1999, pp. 348-352
Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study
Authors: Close, CF Collins, A Gregory, W Goodwin, A Hill, C Jarrett, RJ Jones, SL Keen, H Scott, GS Viberti, G Vora, H Yip, J Grenfell, A Sampson, MJ Watkins, PJ Fishwick, C Gatling, W Hill, RD Marshall, SM Coates, P Owens, DR Peters, JR Vora, J Warren, S
Citation: Cf. Close et al., Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study, DIABET MED, 16(11), 1999, pp. 918-925
Should we screen for microalbuminuria in essential hypertension?
Authors: Viberti, G Thomas, S
Citation: G. Viberti et S. Thomas, Should we screen for microalbuminuria in essential hypertension?, AM J KIDNEY, 34(6), 1999, pp. 1139-1141
Register of randomised trials
Authors: Keen, H Viberti, G
Citation: H. Keen et G. Viberti, Register of randomised trials, LANCET, 354(9191), 1999, pp. 1736-1736
Why do we have to invoke genetic susceptibility for diabetic nephropathy?
Authors: Viberti, G
Citation: G. Viberti, Why do we have to invoke genetic susceptibility for diabetic nephropathy?, KIDNEY INT, 55(6), 1999, pp. 2526-2527
Risultati: 1-13 |